Prescription Drugs · Cardiometabolic Therapeutics
Eli Lilly and Company: Funding & valuation
Eli Lilly and Company returned $9.5B to shareholders in fiscal 2025 and paid $10.8B of income tax.
Financials
Revenue of $65.2B in 2025. +44.7% on the year before. Net income $20.6B.
$65.2BRevenue2025 · +44.7%
$20.6BNet income2025 · +94.9%
$713.1BMarket cap2025
38,350Employees2018
Revenue by yearas filed, with the net income
Money by yearUSD, rounds and grants
Sources: SEC
Money
Eli Lilly and Company returned $9.5B to shareholders in fiscal 2025 and paid $10.8B of income tax.
$10.8BIncome taxes paidFY2025
$9.5BDividends and buybacksFY2025
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
$98kPaid
$1.5MPaid
Loan or credit · Societe Generale, London Branch
Jun 2002 – Dec 2018 · Charge: Charge over equipment
not statedPaid
1 more record: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
From its filingssec.gov ↗
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Income taxes paid | $5.6B | $6.6B | $10.8B |
| Dividends paid | $4.1B | $4.7B | $5.4B |
| Shares bought back | $750M | $2.5B | $4.1B |
| Stock-based compensation | $629M | $646M | $626M |
| Acquisitions, net of cash | – | – | – |
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
